Many untreatable blinding diseases involve degeneration of retinal pigmented epithelial (RPE) cells, which has prompted exploration of the therapeutic potential of human-pluripotent-stem-cell-derived RPE. The first safety trials reported in The Lancet of embryonic-stem-cell-derived RPE cell transplants indicate no serious adverse outcomes and encourage further investigation.
Copyright © 2014 Elsevier Inc. All rights reserved.